Trending

ALS

Blow to Biogen as ALS hope tofersen flunks phase 3 trial

Blow to Biogen as ALS hope tofersen flunks phase 3 trial

Already struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback

X

Blow to Biogen as ALS hope tofersen flunks phase 3 trial

https://pharmaphorum.com/news/blow-to-biogen-as-als-hope-tofersen-flunks-phase-3-trial/

Health Innovators: Teresa Arroyo-Gallego, nQ Medical

Health Innovators: Teresa Arroyo-Gallego, nQ Medical

In this episode of our Health Innovators series, Paul Tunnah is joined by Teresa Arroyo-Gallego, chief data scientist

X

Health Innovators: Teresa Arroyo-Gallego, nQ Medical

https://pharmaphorum.com/video/health-innovators-teresa-arroyo-gallego-nq-medical/

Tackling diabetes & ALS with cell therapy

Tackling diabetes & ALS with cell therapy

Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells

X

Tackling diabetes & ALS with cell therapy

https://pharmaphorum.com/views-and-analysis/tackling-diabetes-als-with-cell-therapy/

BMS joins forces with insitro to develop neurodegenerative treatments

BMS joins forces with insitro to develop neurodegenerative treatments

insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies

X

BMS joins forces with insitro to develop neurodegenerative treatments

https://pharmaphorum.com/news/bms-joins-forces-with-insitro-to-develop-neurodegenerative-treatments/

The ALS patient journey

The ALS patient journey

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). ALS is a progressive

X

The ALS patient journey

https://pharmaphorum.com/partner-content/the-als-patient-journey/

Mitsubishi Tanabe pulls ALS drug from EMA assessment

Mitsubishi Tanabe pulls ALS drug from EMA assessment

Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements

X

Mitsubishi Tanabe pulls ALS drug from EMA assessment

https://pharmaphorum.com/news/mitsubishi-tanabe-pulls-als-drug-from-ema-assessment/

AI-discovered candidates show promise in ALS

AI-discovered candidates show promise in ALS

Candidates slow down motor neurone death in patient samples.

X

AI-discovered candidates show promise in ALS

https://pharmaphorum.com/news/ai-candidates-motor-neurone-disease/

FDA approves first ALS treatment for two decades

FDA approves first ALS treatment for two decades

FDA asked Mitsubishi to file Radicava following approval in Japan.

X

FDA approves first ALS treatment for two decades

https://pharmaphorum.com/news/fda/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com